Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • Marco0208
    Junior Member
    • Nov 2012
    • 6

    Exome Sequencing vs Target Region Sequencing

    Hi guys

    What is the difference between Exome sequencing & Target region sequencing ?

    I know roughly exome sequencing only sequences exons and Target region sequencing sequences specific regions/ genes.

    But what confuses me is the methods and procedures.
    Both Agilent Sure-Select kits and NimbleGen Kits are involved in both sequencing methods ..... and are they the same workflow ?

    Cheers
  • frostzwerg
    Junior Member
    • Nov 2012
    • 2

    #2
    Hi Marco,

    In principle yes, exome sequencing and target region sequencing are the same, using the same workflow!

    In more detail, exome enrichment is one part of target region enrichment (if you define your target region as the exome). If you define your target region as say 100 genes of interest, then you have to use some modified bait sequences to enrich the targets you want to sequence.

    Comment

    • Marco0208
      Junior Member
      • Nov 2012
      • 6

      #3
      Hi

      Thanks for the reply.

      Strange because my colleague told me the methods for both sequencings are different !!! Anyway, i know that at least Exome is for Exon sequencing and Target Region sequencing is for any genes.

      One of reasons why i though both methods are the same is because of the capture platform .....

      For Exome Sequencing, it saids Agilent SureSelect Human ALL & NimbleGen SeqCap EZ Exome

      For Target Region Sequencing, it saids Main Capture arrays/kits OR personalized capture kits from Agilent SureSelect and NimbleGen Kits

      Are the methods = same???

      But i was asked to present on both topics !!! I am getting more confused because i always thought they were the same apart from the targeted genome !!!

      PLEASE HELP !!!!

      Comment

      • TonyBrooks
        Senior Member
        • Jun 2009
        • 303

        #4
        Exome sequencing IS targetted region sequencing. The targetted region is the exome (exons). Baits are designed against those regions to pull down library fragments that come from those regions of the genome. At the moment, due to enrichment size (tens of Mb) this is really the only way to enrich for the exome.
        Targetted region sequencing can be done in the same way, using the same protocol, but by requesting other genomic regions (any thing above a few kb). These regions can be a sub-set of the exome (you may not want to sequence every gene) or perhaps you want more intronic regions or UTRs from certain genes that aren't on the exome panel of choice. There are large economies of scale so unless you plan on running hundreds of custom regions it's sometimes cheaper to go for an off the shelf exome.
        The sequencing methods of both will be the same (although obviously, if you're sequencing smaller regions, you don't need as many reads). In fact, for most applications you rarely need to alter how you sequence, just how much.

        However, there are other methods for targetted sequencing (really only suitable for smaller regions of interest) such as amplicon sequencing. Examples of these are Illumina's TruSeq Custom Amplicon, Agilent's Haloplex, Raindance, Fluidigm and AmpliSeq from Life.
        Amplicon sequencing can't enrich for regions as large as an exome (at this moment in time).

        Comment

        • buckybadger
          Member
          • Aug 2013
          • 15

          #5
          The most basic differences between the Agilent SureSelect and NimbleGen Kits are that the Agilent kits use biotinylated RNA oligonucleotide probes with 65 deg C hybridization temperature, while the NimbleGen Kits use biotinylated DNA oligonucleotide probes with 47 deg C hybridization temperature. There will also be differences in the buffers they use. Another, often under-appreciated, difference between the two products is the bioinformatics expertise and algorithms behind the probe selection process. Both can use Illumina compatible sequencing libraries as input.

          Here are some relevant links that were recently published:

          Isolating high-priority segments of genomes greatly enhances the efficiency of next-generation sequencing (NGS) by allowing researchers to focus on their regions of interest. For the 2010-11 DNA Sequencing Research Group (DSRG) study, we compared outcomes from two leading companies, Agilent Technolo …





          Cheers,

          --BB

          Comment

          Latest Articles

          Collapse

          • mylaser
            Reply to Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by mylaser
            Kheloyaar: The Complete Guide to Kheloyaar Loginand Kheloyaar ID
            The online gaming industry has transformed the way people enjoy digital entertainment. As technology continues to improve, players are looking for platforms that offer convenience, security, and a seamless user experience. Kheloyaarhas gained attention among users who value an easy-to-use platform, quick account access, and a simple registration process.
            Whether you're exploring Kheloyaar for the first time or want to understand...
            Today, 09:27 PM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            Today, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            Yesterday, 05:17 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, Today, 10:04 AM
          0 responses
          8 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, Yesterday, 10:08 AM
          0 responses
          7 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-07-2026, 11:05 AM
          0 responses
          10 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-02-2026, 11:08 AM
          0 responses
          31 views
          0 reactions
          Last Post SEQadmin2  
          Working...